Notes from the Eigth International Kidney Cancer Symposium
Conclusions on Optimal Systemic Control For High Risk Patients:
- Anti-angiogenic agents are capable of reducing primary tumors, but not consistently.
- There is no evidence that anti-angiogenic agents are anti-metastatic
- Monitoring tools/markers need to be developed that can measure efficacy of anti-metastatic drugs
As a patient advocate I point out that in the summary table of neoadjuvant trials results for local control: There is a learning curve to use these drugs safely and effectively. The current neoadjuvant therapy approaches were safe in the hands of experienced clinicia...
Source: Kidney Cancer Association - January 25, 2010 Category: Urology & Nephrology Source Type: news
Notes from the Eigth International Kidney Cancer Symposium
Conclusions on OptimalSystemic Control For High Risk Patients: - Anti-angiogenic agents are capable of reducing primary tumors, but not consistently. - There is no evidence that anti-angiogenic agents are anti-metastatic - Monitoring tools/markers need to be developed that can measure efficacy of anti-metastatic drugs As a patient advocate I point out that in the summary table of neoadjuvant trials results for local control: There is a learning curve to use these drugs safely and effectively. The current neoadjuvant therapy approaches were safe in the hands of experienced clinicians&hel...
Source: Kidney Cancer Association - January 25, 2010 Category: Urology & Nephrology Source Type: news
Patient Advocate's Notes From 8th International Kidney Cancer Symposium
Conclusions on OptimalSystemic Control For High Risk Patients: - Anti-angiogenic agents are capable of reducing primary tumors, but not consistently. - There is no evidence that anti-angiogenic agents are anti-metastatic - Monitoring tools/markers need to be developed that can measure efficacy of anti-metastatic drugs AS a patient advocate I point out that in the summary table of neoadjuvant trials results for local control: There is a learning curve to use these drugs safely and effectively. The current neoadjuvant therapy approaches were safe in the hands of experienced clinicians... an example ...
Source: Kidney Cancer Association - January 4, 2010 Category: Urology & Nephrology Source Type: news
Patient Advocate's Notes From 8th International Kidney Cancer Symposium
Conclusions on Optimal Systemic Control For High Risk Patients:
- Anti-angiogenic agents are capable of reducing primary tumors, but not consistently.
- There is no evidence that anti-angiogenic agents are anti-metastatic
- Monitoring tools/markers need to be developed that can measure efficacy of anti-metastatic drugs
AS a patient advocate I point out that in the summary table of neoadjuvant trials results for local control: There is a learning curve to use these drugs safely and effectively. The current neoadjuvant therapy approaches were safe in the hands of experienced clinicians... an ex...
Source: Kidney Cancer Association - January 4, 2010 Category: Urology & Nephrology Source Type: news
Patient Advocate's Notes From 8th International Kidney Cancer Symposium
Conclusions on OptimalSystemic Control For High Risk Patients: - Anti-angiogenic agents are capable of reducing primary tumors, but not consistently. - There is no evidence that anti-angiogenic agents are anti-metastatic - Monitoring tools/markers need to be developed that can measure efficacy of anti-metastatic drugs AS a patient advocate I point out that in the summary table of neoadjuvant trials results for local control: There is a learning curve to use these drugs safely and effectively. The current neoadjuvant therapy approaches were safe in the hands of experienced clinicians... an example ...
Source: Kidney Cancer Association - January 4, 2010 Category: Urology & Nephrology Source Type: news
Notes from the 8th International Symposium
Patient advocates generously volunteered their time to take notes at the recent 8th International Kidney Cancer Symposium, in Chicago. These notes are intended to capture the essence of this important medical meeting and convey it in a way that is useful to patients, survivors, and their families. The first installment sumarizes the Saturday morning session.Integration of Surgical and Systemic Therapy in Metastatic RCC This session was opened by Dr. Bradley Leibovich who presented two cases on which the audience voted on methods to integrate surgery with systemic treatment interventions. The diversit...
Source: Kidney Cancer Association - November 17, 2009 Category: Urology & Nephrology Source Type: news
Notes from the 8th International Symposium
Patient advocates generously volunteered their time to take notes at the recent 8th International Kidney Cancer Symposium, in Chicago. These notes are intended to capture the essence of this important medical meeting and convey it in a way that is useful to patients, survivors, and their families. The first installment sumarizes the Saturday morning session.
Integration of Surgical and Systemic Therapy in Metastatic RCC
This session was opened by Dr. Bradley Leibovich who presented two cases on which the audience voted on methods to integrate surgery with systemic treatment interventions. T...
Source: Kidney Cancer Association - November 17, 2009 Category: Urology & Nephrology Source Type: news
Notes from the 8th International Symposium
Patient advocates generously volunteered their time to take notes at the recent 8th International Kidney Cancer Symposium, in Chicago. These notes are intended to capture the essence of this important medical meeting and convey it in a way that is useful to patients, survivors, and their families. The first installment sumarizes the Saturday morning session.Integration of Surgical and Systemic Therapy in Metastatic RCC This session was opened by Dr. Bradley Leibovich who presented two cases on which the audience voted on methods to integrate surgery with systemic treatment interventions. The diversit...
Source: Kidney Cancer Association - November 17, 2009 Category: Urology & Nephrology Source Type: news
Targeted Therapy Improves Survival in Poor-Risk Renal Cancer
Patients with poor-risk renal cell carcinoma have improved survival with temsirolimus (Torisel) whether they have a nephrectomy or not.03/04/2009 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 4, 2009 Category: Cancer & Oncology Source Type: news
Nephron-Sparing Surgery Possible When Treating Renal Cancer
By medinews.com staff writers
Posted on
var monthNames = new Array(
"January","February","March","April","May","June","July","August","September","October","November","December");
document.write("09 " + monthNames[01-1] +" 2008" );
09 January 2008
Nephron-sparing surgery is a safe alternative to radical nephrectomy in selected patients with locally advanced renal cell carcinoma, according to a new study.
Researchers at the University of Texas MD Anderson Cancer Center (Houston, TX, USA) retrospecti...
Source: Kidney Cancer Association - January 16, 2008 Category: Urology & Nephrology Source Type: news
